Pacira BioSciences, Inc. (PCRX)

$58.14

+0.19 (+0.33%)
Rating:
Recommendation:
Buy
Symbol PCRX
Price $58.14
Beta 0.842
Volume Avg. 0.45M
Market Cap 2.664B
Shares () -
52 Week Range 45.05-82.16
1y Target Est -
DCF Unlevered PCRX DCF ->
DCF Levered PCRX LDCF ->
ROE 5.38% Neutral
ROA 2.26% Neutral
Operating Margin -
Debt / Equity 129.17% Buy
P/E 70.05 Strong Buy
P/B 3.50 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest PCRX news


Mr. David Stack
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Global Select

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.